SFI
EVFM

Susquehanna Fundamental Investments’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Susquehanna Fundamental Investments’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-24,483
Closed -$867K – 1660
2020
Q3 		$867K Buy
24,483
+13,316
+119% +$579K 0.03% 688
2020
Q2 		$474K Buy
+11,167
New +$753K 0.02% 629

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TWMP
Taylor Wealth Management Partners Boston, Massachusetts $176M AUM 14.65% 1-Year Est. Return

Susquehanna Fundamental Investments's EVFM Position: Q4 2020 in Review

Susquehanna Fundamental Investments sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2020, closing a stake of 24,483 shares — an estimated $867K sold.

Susquehanna Fundamental Investments first reported a position in EVFM in Q2 2020 and held it in 2 quarters. The position peaked at $867K in Q3 2020. 93 funds tracked by Wall St. Rank hold EVFM as of Q4 2020.

  • Susquehanna Fundamental Investments reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 24,483 Evofem Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $867K.
  • Susquehanna Fundamental Investments first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Evofem Biosciences, Inc. Common Stock position peaked at $867K in Q3 2020.
  • 93 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2020.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2020, filed 16 Feb 2021.